Athira Pharma, Inc. (NASDAQ:ATHA) Sees Significant Decline in Short Interest

Athira Pharma, Inc. (NASDAQ:ATHA) was the target of a large decrease in short interest in December. As of December 31st, there was short interest totalling 1,170,000 shares, a decrease of 17.6% from the December 15th total of 1,420,000 shares. Based on an average trading volume of 4,600,000 shares, the days-to-cover ratio is currently 0.3 days. Approximately 3.3% of the shares of the stock are short sold.

Athira Pharma Stock Performance

Shares of ATHA traded down $0.00 during trading hours on Friday, hitting $0.53. 44,484 shares of the stock were exchanged, compared to its average volume of 173,889. The stock’s 50-day moving average price is $0.61 and its two-hundred day moving average price is $1.39. The company has a market cap of $20.51 million, a price-to-earnings ratio of -0.19 and a beta of 2.99. Athira Pharma has a 12-month low of $0.41 and a 12-month high of $4.30.

Athira Pharma (NASDAQ:ATHA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.75) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.05. On average, research analysts expect that Athira Pharma will post -2.35 earnings per share for the current year.

Institutional Trading of Athira Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in ATHA. XTX Topco Ltd acquired a new stake in Athira Pharma during the second quarter worth $60,000. Invst LLC purchased a new position in shares of Athira Pharma during the 2nd quarter worth $68,000. American Century Companies Inc. increased its position in shares of Athira Pharma by 9.4% during the 2nd quarter. American Century Companies Inc. now owns 38,940 shares of the company’s stock worth $103,000 after purchasing an additional 3,333 shares during the last quarter. Forefront Analytics LLC raised its holdings in Athira Pharma by 126.0% in the 2nd quarter. Forefront Analytics LLC now owns 46,595 shares of the company’s stock valued at $123,000 after buying an additional 25,979 shares during the period. Finally, Bristlecone Advisors LLC lifted its position in Athira Pharma by 295.6% in the third quarter. Bristlecone Advisors LLC now owns 337,506 shares of the company’s stock valued at $151,000 after buying an additional 252,200 shares during the last quarter. Institutional investors and hedge funds own 57.12% of the company’s stock.

Analyst Ratings Changes

Separately, Mizuho cut Athira Pharma from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $5.00 to $0.50 in a report on Thursday, September 19th.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.